JP2017531013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531013A5 JP2017531013A5 JP2017520388A JP2017520388A JP2017531013A5 JP 2017531013 A5 JP2017531013 A5 JP 2017531013A5 JP 2017520388 A JP2017520388 A JP 2017520388A JP 2017520388 A JP2017520388 A JP 2017520388A JP 2017531013 A5 JP2017531013 A5 JP 2017531013A5
- Authority
- JP
- Japan
- Prior art keywords
- liver disease
- composition
- item
- fatty liver
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 208000010706 fatty liver disease Diseases 0.000 claims description 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 4
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 4
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 125000003158 alcohol group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064358P | 2014-10-15 | 2014-10-15 | |
| US62/064,358 | 2014-10-15 | ||
| US201462092041P | 2014-12-15 | 2014-12-15 | |
| US62/092,041 | 2014-12-15 | ||
| PCT/US2015/055487 WO2016061195A1 (en) | 2014-10-15 | 2015-10-14 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531013A JP2017531013A (ja) | 2017-10-19 |
| JP2017531013A5 true JP2017531013A5 (enExample) | 2018-11-22 |
| JP6761410B2 JP6761410B2 (ja) | 2020-09-23 |
Family
ID=55747256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520388A Active JP6761410B2 (ja) | 2014-10-15 | 2015-10-14 | グルココルチコイドおよびミネラル・コルチコイドレセプターアンタゴニストを使用する脂肪肝疾患の処置 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10238659B2 (enExample) |
| EP (3) | EP4792880A2 (enExample) |
| JP (1) | JP6761410B2 (enExample) |
| KR (1) | KR102435956B1 (enExample) |
| CN (2) | CN107106562B (enExample) |
| AU (1) | AU2015333645B2 (enExample) |
| BR (1) | BR112017007860B1 (enExample) |
| CA (1) | CA2964625C (enExample) |
| DK (2) | DK4353310T3 (enExample) |
| ES (1) | ES2978871T3 (enExample) |
| FI (2) | FI4353310T3 (enExample) |
| IL (1) | IL251729B (enExample) |
| MX (1) | MX2017004943A (enExample) |
| NZ (1) | NZ731060A (enExample) |
| PH (1) | PH12017500710B1 (enExample) |
| PL (1) | PL3206692T3 (enExample) |
| PT (2) | PT4353310T (enExample) |
| RU (1) | RU2718921C2 (enExample) |
| SG (1) | SG11201703024VA (enExample) |
| UA (1) | UA123537C2 (enExample) |
| WO (1) | WO2016061195A1 (enExample) |
| ZA (1) | ZA201702813B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703024VA (en) | 2014-10-15 | 2017-05-30 | Corcept Therapeutics Inc | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
| CA3102099C (en) * | 2018-06-04 | 2023-09-26 | Corcept Therapeutics Incorporated | Pyrimidine cyclohexenyl glucocorticoid receptor modulators |
| AU2020239920A1 (en) | 2019-03-18 | 2021-11-04 | Arnold L. Newman | Method of improving insulin sensitivity |
| KR102911885B1 (ko) | 2020-05-06 | 2026-01-12 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제의 다형체 |
| AU2021266739B2 (en) * | 2020-05-06 | 2024-11-28 | Corcept Therapeutics Incorporated | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators |
| KR102481705B1 (ko) * | 2020-08-04 | 2022-12-27 | 연세대학교 산학협력단 | 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물 |
| JP7853982B2 (ja) * | 2020-12-21 | 2026-04-30 | コーセプト セラピューティクス， インコーポレイテッド | ピリミジンシクロヘキシルグルココルチコイド受容体調節因子を調製する方法 |
| US12616698B2 (en) | 2021-05-05 | 2026-05-05 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| AU2022271209B2 (en) * | 2021-05-05 | 2026-07-02 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| WO2025174745A1 (en) * | 2024-02-12 | 2025-08-21 | Corcept Therapeutics Incorporated | MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS |
| WO2025255357A1 (en) * | 2024-06-06 | 2025-12-11 | Corcept Therapeutics Incorporated | Methods for preparing and maintaining livers and portions thereof for liver transplantation |
| EP4732836A1 (en) | 2024-10-22 | 2026-04-29 | Consejo Superior De Investigaciones Científicas | Ag5 compound for use in the treatment of in fatty liver diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2153546A (en) | 1936-07-29 | 1939-04-11 | Universal Draft Gear Attachmen | Hand brake actuating mechanism |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB0213745D0 (en) * | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
| JP2006508042A (ja) | 2002-07-18 | 2006-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体の修飾物質および方法 |
| EP1883624B1 (en) | 2005-05-18 | 2010-04-07 | Merck Sharp & Dohme Corp. | D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands |
| US8389472B2 (en) * | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| AU2006292293B2 (en) * | 2005-09-19 | 2012-09-13 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
| GB0601092D0 (en) * | 2006-01-19 | 2006-03-01 | Daniolabs Ltd | The Prevention Of Systemic Side-Effects Of Glucocorticoids |
| ES2546181T3 (es) | 2006-05-09 | 2015-09-21 | Genzyme Corporation | Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US20100144764A1 (en) * | 2007-04-13 | 2010-06-10 | Schering Corporation | Pyrimidinedione derivatives and methods of use thereof |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| CA2738573C (en) | 2009-04-03 | 2013-02-19 | F. Hoffmann-La Roche Ag | Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof |
| CN103596431B (zh) * | 2011-03-18 | 2016-06-22 | 科赛普特治疗公司 | 嘧啶环己基糖皮质激素受体调节剂 |
| SG11201703024VA (en) | 2014-10-15 | 2017-05-30 | Corcept Therapeutics Inc | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
-
2015
- 2015-10-14 SG SG11201703024VA patent/SG11201703024VA/en unknown
- 2015-10-14 FI FIEP24157529.9T patent/FI4353310T3/fi active
- 2015-10-14 PT PT241575299T patent/PT4353310T/pt unknown
- 2015-10-14 CN CN201580068262.4A patent/CN107106562B/zh active Active
- 2015-10-14 DK DK24157529.9T patent/DK4353310T3/da active
- 2015-10-14 MX MX2017004943A patent/MX2017004943A/es active IP Right Grant
- 2015-10-14 FI FIEP15851238.4T patent/FI3206692T3/fi active
- 2015-10-14 EP EP26180646.7A patent/EP4792880A2/en active Pending
- 2015-10-14 NZ NZ731060A patent/NZ731060A/en unknown
- 2015-10-14 PT PT158512384T patent/PT3206692T/pt unknown
- 2015-10-14 ES ES15851238T patent/ES2978871T3/es active Active
- 2015-10-14 KR KR1020177012950A patent/KR102435956B1/ko active Active
- 2015-10-14 EP EP24157529.9A patent/EP4353310B1/en active Active
- 2015-10-14 PH PH1/2017/500710A patent/PH12017500710B1/en unknown
- 2015-10-14 JP JP2017520388A patent/JP6761410B2/ja active Active
- 2015-10-14 EP EP15851238.4A patent/EP3206692B1/en active Active
- 2015-10-14 CA CA2964625A patent/CA2964625C/en active Active
- 2015-10-14 PL PL15851238.4T patent/PL3206692T3/pl unknown
- 2015-10-14 BR BR112017007860-0A patent/BR112017007860B1/pt active IP Right Grant
- 2015-10-14 CN CN202010597452.8A patent/CN111557942B/zh active Active
- 2015-10-14 UA UAA201704069A patent/UA123537C2/uk unknown
- 2015-10-14 AU AU2015333645A patent/AU2015333645B2/en active Active
- 2015-10-14 RU RU2017114596A patent/RU2718921C2/ru active
- 2015-10-14 DK DK15851238.4T patent/DK3206692T3/da active
- 2015-10-14 US US14/883,369 patent/US10238659B2/en active Active
- 2015-10-14 WO PCT/US2015/055487 patent/WO2016061195A1/en not_active Ceased
-
2017
- 2017-04-13 IL IL251729A patent/IL251729B/en active IP Right Grant
- 2017-04-21 ZA ZA2017/02813A patent/ZA201702813B/en unknown
-
2019
- 2019-01-24 US US16/256,295 patent/US10881660B2/en active Active
-
2020
- 2020-12-03 US US17/111,288 patent/US11590135B2/en active Active
-
2023
- 2023-01-26 US US18/101,986 patent/US12226417B2/en active Active
-
2025
- 2025-01-09 US US19/014,779 patent/US20250221995A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017114596A (ru) | Лечение жировой болезни печени с применением антагонистов глюкокортикоидных и минералокортикоидных рецепторов | |
| JP2014015465A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| JP2018510139A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| AR074165A1 (es) | Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas | |
| JP2011137045A5 (enExample) | ||
| JP2016525130A5 (enExample) | ||
| JP2020521766A5 (enExample) | ||
| AR072241A1 (es) | Antagonistas de aminoalquilbifenilo n,n-disustituidos de receptores de prostaglandina d2 y composiciones farmaceuticas que los comprenden | |
| JP2016516043A5 (enExample) | ||
| EA201400234A1 (ru) | Фунгицидные замещенные 1-{2-[2-галоген-4(4-галогенфенокси)фенил]-2-алкинилоксиэтил}-1н-[1,2,4]триазолные соединения | |
| JP2016537478A5 (enExample) | ||
| JP2016515096A5 (enExample) | ||
| JP2016503052A5 (enExample) | ||
| JP2015512946A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| EA201400232A1 (ru) | Фунгицидные замещенные 1-{2-[2-галоген-4-(4-галогенфенокси)фенил]-2-алкокси-2-циклилэтил}-1н-[1,2,4]триазольные соединения | |
| JP2006524660A5 (enExample) | ||
| EA201592020A1 (ru) | Новая композиция для неалкогольной жировой болезни печени (нажбп) | |
| JP2018135343A5 (enExample) | ||
| EA202191250A1 (ru) | Смеси и композиции, включающие 5-фтор-4-имино-3-метил-1-тозил-3,4-дигидропиримидин-2-он, и способы их применения | |
| RU2016133471A (ru) | Композиции и способы для лечения диабета и заболеваний печени | |
| JP2017533263A5 (enExample) | ||
| EA201600241A1 (ru) | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты |